SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-034431
Filing Date
2024-03-21
Accepted
2024-03-21 08:08:03
Documents
12
Period of Report
2024-03-21
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K labp-20240321.htm   iXBRL 8-K 39284
2 EX-99.1 labp-ex99_1.htm EX-99.1 136026
  Complete submission text file 0000950170-24-034431.txt   298269

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT labp-20240321.xsd EX-101.SCH 24863
15 EXTRACTED XBRL INSTANCE DOCUMENT labp-20240321_htm.xml XML 4696
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39971 | Film No.: 24769547
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)